Profil's Publications

Recent Publications

• Mather KJ, Mari A, Heise T, DeVries JH, Hua M, Urva S, Coskun T, Haupt A, Heine RJ, Pratt E, Thomas MK, Milicevic Z.
  Effects of tirzepatide vs semaglutide on beta-cell function, insulin sensitivity, and glucose control during a meal test.
  J CLIN ENDOCRINOL METAB 2024 May 26. doi: 10.1210/clinem/dgae319. Online ahead of print. 
• Ambery P, Zajac G, Almquist J, Prothon S, Astbury C, Brown MN, Nemes S, Nsabimana J, Edman K, Öberg L, Lepistö M, Edenro G, Dillmann I, Mitra S, Belfield G, Keen C, Heise T.
  The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial.
  BR J CLIN PHARMACOL 2024 May 1. doi: 10.1111/bcp.16082. Online ahead of print.
• Hövelmann U, Engberg S, Heise T, Kristensen NR, Norgreen L, Zijlstra E, Ribel-Madsen R.
  Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
  DIABETES OBES METAB 26: 1941-1949, 2024
• Leohr J, Dellva MA, LaBell E, Coutant DE, Arrubla J, Plum-Mörschel L, Zijlstra E, Fukuda T, Hardy T.
  Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
  DIABETES OBES METAB 2023 Oct 9. doi: 10.1111/dom.15307. Online ahead of print.
• Chen W, Lu J, Plum-Mörschel L, Andersen G, Zijlstra E, He A, Xie T, Li L, Hao C, Gan Z, Heise T.
  Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- and US-sourced reference insulins.
  DIABETES OBES METAB 2023 Sep 21. doi: 10.1111/dom.15281. Online ahead of print.
• Heller S, Battelino T, Bailey TS, Pieber TR, Hövelmann U, Plum-Mörschel L, Melgaard AE, Aronson R, DiMeglio LA, Johansen T, Danne T.
  Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.
  DIABETES OBES METAB 2023; 25 (5): 1351-1360
• Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T.
  Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes.
  DIABETES CARE 2023; 46 (5): 998-1004 
• Heise T, Chien J, Beals JM, Klein O, Moyers JS, Haupt A, Pratt EJ.
  Pharmacokinetic and pharmcodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes.
  DIABETES OBES METAB 2023; 25 (4): 1080-1090
• Jungnik A, Arrubla Martinez J, Plum-Mörschel L, Kapitza C, Lamers D, Thamer C, Schölch C, Desch M, Hennige AM.
  Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
  DIABETES OBES METAB 2023; 25 (4): 1011-1023
• Handy C, Chaudhry MS, Qureshi MRA, Love B, Shillingford J, Plum-Mörschel L, Zijlstra E.
  Noninvasive continuous glucose monitoring with a novel wearable dial resonating sensor: A clinical Proof-of-Concept Study.
  J DIABETES SCI TECHNOL 2023 Apr 27. doi: 10.1177/19322968231170242. 
• Bianzano S, Nordaby M, Plum-Mörschel L, Peil B, Heise T.
  Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
  DIABETES OBES METAB 2023; 25 (3): 832-843
• Garhyan P, Pratt E, Klein O, Famulla S, Zijlstra E, Lalonde A, Swinney M, Kazda C, Dassau E.
  Evaluation of insulin lispro pharmacokinetics and pharmacodynamics over 10 days of continuous insulin infusion in people with type 1 diabetes.
  J DIABETES SCI TECHNOL 2023; 17 (2): 274-282
• Plum-Mörschel L, Andersen LR, Hansen S, Hövelmann U, Krawietz P, Kristensen NR, Lehrskov LL, Haahr H.
  Pharmacokinetic and pharmacodynamic characteristics of insulin icodec after subcutaneous administration in the thigh, abdomen or upper arm in individuals with type 2 diabetes.
  CLIN DRUG INVESTIG 2023; 43 (2): 119-127
• Heise T, Plum-Mörschel L, Zijlstra E.
  Oral insulin: a history of ambition, failure and data torturing.
  DIABETES OBES METAB 2023 Jan 24. doi: 10.1111/14984. Online ahead of print.
• Andersen G, Eloy R, Famulla S, Heise T, Meiffren G, Seroussi C, Gaudier M, Megret C, Chan YP, Soula O, Riddle M.
  A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.
  DIABETES OBES METAB 2023 Jan 12. doi: 10.1111/dom.14972. Online ahead of print.
• Eckstein ML, Aberer F, Dobler FJR, Aziz F, Heise T, Sourij H, Moser O.
  Association of HbA1c with VO2max in individuals with type 1 diabetes: A systematic review and meta-analysis.
  METABOLITES 2022, 12, 1017. doi.org/10.3390/metabol 1211017
• Borgmann SO, Verket M, Gontscharuk V, Bücker B, Arnolds S, Spörkel O, Wilm S, Icks A.
  Diabetes-related research priorities of people with type 1 and type 2 diabetes: a cross-sectional study in Germany.
  SCI REP 2022 Dec 2; 12 (1): 20835. doi: 10.1038/s41598-022-24180-y 
• Bianzano S, Schepers C, Wolff M, Heise T, Plum-Mörschel L.
  Selective inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI187004 in patients with type 2 diabetes and overweight or obesity: Safety, pharmacokinetics, and pharmacodynamics after multiple dosing over 14 days.
  EXP CLIN ENDOCRINOL DIABETES 2022 Nov 7. doi: 1055/a-1932-3136. Online ahead of print.
• Ignaut D, Fukuda T, Bandi R, Ermer M, Stoffel MS, Zijlstra E, Paavola C.
  An investigation into local infusion site pain after infusion of ultra rapid lispro excipients across sites and depths.
  J DIABETES SCI TECHNOL 2022 Nov 3. doi: 10.1177/19322968221135217. Online ahead of print.
• Heise T, Piras de Oliveira C, Juneja R, Ribeiro A, Chigutsa F, Blevins T.
  What is the value of faster acting prandial insulin?
  Focus on ultra rapid lispro.
  DIABETES OBES METAB 2022 May 19. doi: 10.1111/dom.14773. Online ahead of print.
• Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z.
  Effects of tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
  LANCET DIABETES ENDOCRINOL 10: 418-429, 2022
• Heise T.
  Novel drugs for diabetes therapy.
  HANDB EXP PHARMACOL 2022 Feb 3. doi: 10.1007/164_2021_574. Online ahead of print.
• Lizzo G, Migliavacca E, Lamers D, Frezal A, Corthesy J, Vinyes-Pares G, Bosco N, Karagounis LG, Hövelmann U, Heise T, von Eynatten M, Gut P.
  A randomized controlled clinical trial in healthy older adults to determine efficacy of glycine and N-Acetylcysteine supllementation on glutathione redox status and oxidative damage.
  FRONT AGING 2022 Mar 07, 3:852569. doi: 10.3389/fragi.2022.852569  
• Plum-Mörschel L, Klein O, Singh G, Murugesan SMN, Marwah A, Sharma N, Panda J, Loganathan S, Lakshmi GC, Athalye SN.
  Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN 70/30 formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.
  DIABETES OBES METAB 24: 713-721, 2022
• Meier JJ, Quast DR, Nauck MA, Schenker N, Deacon CF, Holst JJ, Plum-Mörschel L. Kapitza C.
  Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without modreate renal impairment.
  DIABETES OBES METAB 24: 806-815, 2022
• Grant M, Heise T, Baughman R.
  Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus.
  CLIN PHARMACOKINET 61: 413-422, 2022
• Meier JJ, Granhall C, Hoevelmann U, Navarria A, Plum-Moerschel L, Ramesh C, Tannapfel A, Kapitza C.
  Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
  DIABETES OBES METAB 24: 684-692, 2022
• Bianzano S. Heise T, Jungnik A, Schepers C, Schölch C, Gräfe-Mody U.
  Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
  CLIN DIABETES ENDOCRINOL 2021 Aug 15; 7(1):16. doi: 10.1186/s40842-021-00130-x
• Leohr J, Kazda C, Liu R, Reddy S, Dellva MA, Matzopoulos M, Loh MT, Hardy T, Klein O, Kapitza C.
  Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study.
  DIABETES OBES METAB 2021 Oct 4. doi: 10.1111/dom.14561. Online ahead of print.
• Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Palle MS, Vogl T, Loomba R, Plum-Mörschel L.
  Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
  ALIMENT PHARMACOL THER 2021 Sep 27. doi:10.1111/apt.16608. Online ahead of print.
• Hövelmann U, Reiter Y, Chullikana A, Liu M, Donnelly C, Lawrence T, Sengupta N, Cl G, Ranganna G, Barve A.
  Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.
  DIABETES OBES METAB 2021 Aug 11. doi: 10.1111/dom.14519. Online ahead of print.
• Quast DR, Nauck MA, Schenker N, Menge BA, Kapitza C, Meier JJ.
  Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting GLP-1 receptor agonists in type 2 diabetes.
  DIABETES OBES METAB 2021 Jun 29. doi: 10.1111/dom.14477. Online ahead of print 
• Heise T.
  The future of insulin therapy. 
  DIABETES RES CLIN PRACT 2021 Apr 16; 175:108820. doi:10.1016/j.diabres.2021.108820. Online ahead of print
• Pieber TR, Aronson R, Hövelmann U, Willard J, Plum-Mörschel L, Knudsen KM, Bandak B, Tehranchi R.
  Dasiglucagon: A next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia. Results of phase 3 randomized double-blind clinical trial.
  DIABETES CARE 44: 1-7, 2021. https://doi.org/10.2337/DC20-2995  
• Moser O, Riddell MC, Eckstein ML, Adolfsson P, Rabasa-Lhoret R, van den Boom L, Gillard P, Norgaard K, Oliver NS, Zaharieva DP, Battelino T, de Beaufort C, Bergenstal RM, Buckingham B, Cengiz E, Deeb A, Heise T, Heller S, Kowalski AJ, Leelarathna L, Mathieu C, Stettler C, Tauschmann M, Thabit H, Wilmot EG, Sourij H, Smart CE, Jacobs PG, Bracken RM, Mader JK. 
  Glucose monitoring for exercise using continuous glucose monitoring: should sex and prandial state be additional requirements? Reply to Yardley JE and Sigal RJ (letter)
  DIABETOLOGIA 64: 935-938, 2021 
• Benesch C, Kuhlenkötter M, Nosek L, Heise T.
  New Clamp-PID Algorithm for automated glucose clamps improves clamp quality.
  J Diabetes Sci Technol 2021 Feb 10. doi: 10.1177/1932296821991514
• Olafsdottir AF, Bolinder J, Heise T, Polonsky W, Ekelund M, Wijkman M, Pivodic A, Ahlen E, Schwarcz E, Nyström T, Hellman J, Hirsch IB, Lind M.
  The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5).
  DIABETES OBES METAB 23: 619-630, 2021
• Lind M, Olafsdottir AF, Hirsch IB, Bolinder J, Dahlqvist S, Pivodic A, Hellman J, Wijkman M, Schwarcz E, Albrektsson H, Heise T, Polonsky W.
  Sustained intensive treatment and long-term effects on HbA1c reduction (SILVER Study) by CGM in people with type 1 diabetes treated with MDI.
  DIABETES CARE 44: 141-149, 2021
• Herbrand T, Coester HV, Sansone R, Fischer A, Heiss C, Heise T, Kelm M, DeVries HJ.
  Improving the assessment of flow-mediated dilation through detection of peak time in healthy subjects and subjects with type 2 diabetes.
  ANGIOLOGY 2020 Dec 30. doi: 10.1177/0003319720984884. Online ahead of print
• Andersen G, Meiffren G, Famulla S, Heise T, Ranson A, Seroussi C, Eloy R, Gaudier M, Charvet R, Chan Y-P, Soula O, DeVries JH.
  ADO09, a co-formulation of the amylin-analog pramlintide and the insulin analog A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes (T1D).
  DIABETES OBES METAB 2020 Dec 18. doi: 10.1111/dom.14302. Online ahead of print. 
• Kapitza C, Nosek L, Schmider W, Teichert L, Mukherjee B, Nowotny I.
  A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.
  DIABETES OBES METAB 2020;1-8 (Early view)
• Eckstein ML. Boufleur Farinha J, McCarthy O, West DJ, Yardley JE, Bally L, Zueger T, Stettler C, Boff W, Reischak-Oliveira A, Riddell MC, Zaharieva DP, Pieber TR, Müller A, Birnbaumer P, Aziz F, Brugnara L, Haahr H, Zijlstra E, Heise T, Sourij H, Roden M, Hofmann P, Bracken RM, Pesta D, Moser O.
  Differences in physiological responses to cardiopulmonary exercise testing in adults with and without type 1 diabetes: A pooled analysis.
  DIABETES CARE 2020 Nov 12. doi: 10.2337/dc20-1496. Online ahead of print.
• Gruchala A, Cypryk K, Schliess F, Bobeff K, Heise T, Gurdala M, Szadkowska A, Mianowska B.
  Pains and needs of patients with type 2 diabetes as targets for novel technologies.
  CLINICAL DIABETOLOGY 2020, 9. doi: 10.5603/DK.2020.0052
• Stegbauer C, Falivena C, Moreno A, Hentschel A, Rosenmöller M, Heise T, Szecsenyi J, Schliess F.
  Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies.
  BMC HEALTH SERVICES RESEARCH 2020 Nov 16; 20(1): 1043.
• Jones A, Bardram JE, Baekgaard P, Cramer-Petersen CL, Skinner T, Vrangbaek K, Starr L, Norgaard K, Lind N, Bechmann Christensen M, Glümer C, Wang-Sattler R, Laxy M, Brander E, Heinemann L, Heise T, Schliess F, Ladewig K, Kownatka D.
  Integrated personalized diabetes management goes Europe: A multi-disciplinary approach to innovating type 2 diabetes care in Europe.
  PRIM CARE DIABETES 2020 Nov 9;S1751-9918(20)30293-X. doi: 10.1016/j.pcd.2020.10.008. Online ahead of print
• Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA.
  Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial.
  Br J Clin Pharmacol 2020 Oct 30. doi: 10.1111/bcp.14632. Online ahead of print
• Moser O, Riddell MC, Eckstein ML, Adolfsson P, Rabasa-Lhoret R, van den Boom L, Gillard P, Norgaard K, Oliver NS, Zaharieva DP, Battelino T, de Beaufort C, Bergenstal RM, Buckingham B, Cengiz E, Deeb A, Heise T, Heller S, Kowalski A, Leelarathna L, Mathieu C, Stettler C, Tauschmann M, Thabit H, Wilmot EG, Sourij H, Smart CE, Jacobs PG, Bracken RM, Mader JK.
  Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA).
  DIABETOLOGIA 2020 Oct 13. doi: 10.1007/s00125-020-05263-9. Online ahead of print
• Huang J, Huth C, Covic M, Troll M, Adam J, Zukunft S, Prehn C, Wang L, Nano J, Scheerer MF, Neschen S, Kastenmüller G, Suhre K, Laxy M, Schliess F, Gieger C, Adamski J, Hrabe de Angelis M, Peters A, Wang-Sattler R.
  Machine learning approaches revealed metabolic signatures of incident chronic kidney disease in persons with pre- and type 2 diabetes.
  DIABETES 69: 2756-2765, 2020
• Leohr J, Dellva MA, LaBell E, Coutant DE, Klein O, Plum-Moerschel L, Zijlstra E, Linnebjerg H.
  Pharmacokinetic and glucodynamic responses of ultra rapid lispro vs lispro across a clinically relevant range of subcutaneous doses in healthy subjects.
  CLIN THER 42: 1762-1777, 2020
• Andersen G, Plum-Mörschel L, Hockings PD, Morsing A, Palle MS, Svolgaard O, Flint A.
  Clinical characteristics of a non-alcoholic fatty liver disease population across the fibrosis spectrum measured by magnetic resonance elastography: Analysis of screening data.
  ADV THER 2020 Oct 1. doi: 10.1007/s12325-020-01503-x. Online ahead of print
• Seyed Ahmadi S, Westman K, Pivodic A, Olafsdottir AF, Dahlqvist S, Hirsch IB, Hellman J, Ekelund M, Heise T, Polonsky W, Wijkman M, Schwarcz E, Lind M.
  The association between HbA1c and time in hypoglycemia during CGM and self-monitoring of blood glucose in people with type 1 diabetes and multiple daily insulin injections: A randomized clinical trial (GOLD-4).
  DIABETES CARE 2020 Jul 8. doi: 10.2337/dc-19-2606. Online ahead of print
• Quast DR, Schenker N, Menge BA, Nauck MA, Kapitza C, Meier JJ.
  Effects of lixisenatide versus liraglutide (short- and long-acting GLP-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes.
  DIABETES CARE 2020 Jul 9. doi: 10.2337/dc20-0720. Online ahead of print
• Leohr J, Dellva MA, Coutant DE, LaBell E, Heise T, Andersen G, Zijlstra E, Hermanski L, Nosek L, Linnebjerg H.
  Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in patients with type 2 diabetes mellitus: A phase I randomised, crossover study.
  Clin Pharmacokinet 2020 May 29. doi: 10.1007/s40262-020-00901-2. Online ahead of print
• Linnebjerg H, Zhang Q, LaBell E, Dellva MA, Coutant DE, Hövelmann U, Plum-Mörschel L, Herbrand T, Leohr J.
  Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in younger adults and elderly patients with type 1 diabetes mellitus: A randomised controlled trial.
  CLIN PHARMACOKINET 2020 May 29. doi: 10.1007/s40262-020-0093-0. Online ahead of print
• Suico JG, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier BM, Plum-Mörschel L.
  Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: A randomised, open-label, crossover study.
  DIABETES THER 2020 Jun 8. doi: 10.1007/s13300-020-00845-7. Online ahead of print
• Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RIG, Skyler JS, DeVries JH, Renard E, Eckel RH, Zimmet P, Alberti KG, Vidal J, Geloneze B, Chan JC, Ji L, Ludwig B.
  Practical recommendations for the management of diabetes in patients with COVID-19.
  Lancet Diabetes Endocrinol 8: 546-50, 2020 
• Heise T, Linnebjerg H, Coutant D, LaBell E, Zijlstra E, Kapitza C, Bue-Valleskey J, Zhang Q, Dellva MA, Leohr J.
  Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogs: A Phase 1 randomized, crossover study.
  DIABETES OBES METAB 22: 1789-1798, 2020 
• Meier JJ, Menge BA, Schenker N, Erdmann S, Kahle-Stephan M. Schliess F, Kapitza C, Nauck MA.
  Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
  DIABETES OBES METAB 22: 599-611, 2020
• Heise T, Donnelly C, Barve A, Aubonnet P.
  Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and EU insulin glargine formulations in patients with type 1 diabetes mellitus.
  DIABETES OBES METAB 22: 521-529, 2020
• Haahr H, Heise T.
  Fast-acting insulin aspart: A review of its pharmacokinetic and pharmacodynamic properties and clinical consequences.
  CLIN PHARMACOKINET 59: 155-172, 2020 
• Leelarathna L, Thabit H, Wilinska ME, Bally L, Mader JK, Arnolds S, Benesch C, Pieber TR, Shah VN, Carlson AL, Bergenstal RM, Evans ML, Hovorka R, AP@home04 and APCam11 consortia.
  Duration of hybrid closed-loop insulin therapy to achieve representative glycemic outcomes in adults with type 1 diabetes.
  DIABETES CARE 2020 Mar; 43(3):e38-e39. doi: 10.2337/dc19-2041. Epub 2020 Jan 16.
• Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Heike S, Klaus B, Ambery PD, Meier JJ, Hirshberg B.
  Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist.
  J CLIN ENDOCRINOL METAB 2020 Mar 1; 105(3). doi: 10.1210/clinem/dgz047
• Kapitza C, Nosek L, Schneider W, Teichert L, Nowotny I.
  Single-dose euglycemic clamp study demonstrating pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and US- and EU-approved versions of insulin aspart in subjects with type 1 diabetes.
  DIABETES TECHNOL THER 2019 Dec 30. doi:10.1089/dia.2019.0351. (Epub ahead of print)
• Dovc K, Boughton C, Tauschmann M, Thabit H, Bally L, Allen JM, Acerini CL, Arnolds S, de Beaufort C, Bergenstal RM, Criego A, Dunger DB, Elleri D, Evans ML, Fröhlich-Reiterer E, Hofer S, Kapellen T, Leelarathna L, Pieber TR, Rami-Merhar B, Shah VN, Sibayan J, Wilinska ME, Hovorka R; APCam11, AP@Home, and KidsAP Consortia.
  Young children have higher variability of insulin requirements: Observations during hybrid closed-loop insulin delivery.
  DIABETES CARE 42: 1344-137, 2019 
• Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Norgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M.
  Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range.
  DIABETES CARE 2019 Jun 8. doi: 10.2337/dci19-0028. (Epub ahead of print)
• Evans M, Ceriello A, Danne T, De Block C, DeVries JH, Lind M, Mathieu C, Norgaard K, Renard E, Wilmot EG.
  Use of fast-acting insulin aspart in insulin pump therapy in clinical practice.
  DIABETES OBES METAB 21: 2039-2047, 2019
• Halberg IB, Lyby K, Wassermann K, Heise T, Plum-Mörschel L, Zijlstra E.
  The effect of food intake on the pharmacokinetics of oral basal insulin: A randomised crossover trial in healthy male subjects.
  CLIN PHARMACOKINET 2019 May 16. doi: 10.1007/s40262-019-00772-2. (Epub ahead of print)
• Leelarathna L, Thabit H, Wilinska ME, Bally L, Mader JK, Pieber TR, Benesch C, Arnolds S, Johnson T, Heinemann L, Hermanns N, Evans ML, Hovorka R.
  Evaluating glucose control with a novel composite continuous glucose monitoring index.
  J DIABETES SCI TECHNOL 2019 MAR 31. doi: 10.1177/1932296819838525. (Epub ahead of print)
• Meiffren G, Herbrand T, Anastassiadis E, Klein O, DeVries JH, Heise T, Alluis B, Megret C, Gaudier M, Soula O, Plum-Mörschel L.
  Better glycemic control with BioChaperone Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM).
  DIABETES OBES METAB 2019 Mar 3. doi: 10.1111/dom.13685. (Epub ahead of print)
• Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L.
  Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
  LANCET DIABETES ENDOCRINOL 2019 Jan 21. doi: 10.1016/S2213-8587(18)30372-3. (Epub ahead of print)
• Leelarathna L, Thabit H, Wilinska ME, Bally L, Mader JK, Arnolds S, Benesch C, Pieber TR, Shah VN, Carlson AL, Bergenstal RM, Evans ML, Hovorka R, AP@home04 and APCam11 consortia.
  Duration of hybrid closed-loop insulin therapy to achive prepresentative glycemic outcomes in adults with type 1 diabetes.
  Diabetes Care 2020 Jan 16. doi: 10.2337/dc19-2041. Epub ahead of print
• Schloot NC, Hood RC, Corrigan SM, Panek RL, Heise T.
  Concentrated insulins in current clinical practice.
  DIABETES RES CLIN PRACT 2018 Dec 21; 148: 93-101. doi: 10.1016/j.diabres.2018.12.007. (Epub ahead of print)
• Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode B.
  BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
  DIABETES OBES METAB 21: 1066-1070, 2019
• Klonoff DC, Evans ML, Lane W, Kempe HP, Renard E, DeVries JH, Graungaard T, Hyseni A, Gondolf T, Battelino T.
  A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
  DIABETES OBES METAB 2018 Dec 9. doi: 10.1111/dom.13610. (Epub ahead of print) 
• Haahr H, Pieber TR, Mathieu C, Gondolf T, Shiramoto M, Erichsen L, Heise T.
  Clinical pharmacology of fast-acting insulin aspart versus insulin aspart measured as free or total insulin aspart and the relation to anti-insulin aspart antibody levels in subjects with type 1 diabetes mellitus.
  CLINICAL PHARMACOKINETICS 2018 Nov 7. doi: 10.1007/s40262-018-0718-6
• DeVries JH, Bailey TS, Bhargava A, Gerety G, Gumprecht J, Heller S, Lane W, Wysham CH, Zinman B, Bak BA, Hachmann-Nielsen E, Philis-Tsimikas A.
  Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH trials.
  DIABETES OBES METAB 2018 Oct 25. doi: 10.1111/dom.13565. (Epub ahead of print) 
• Hövelmann U, Braendholt Olsen M, Mouritzen U, Lamers D, Kronshage B, Heise T.
  Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
  DIABETES OBES METAB 2018 Oct 23. doi: 10.1111/dom.13562. (Epub ahead of print)
• Al-Qaissi A, Papageorgiou M, Javed Z, Heise T, Rigby AS, Garrett AT, Hepburn D, Kilpatrick ES, Atkin SL, Sathayapalan T.
  Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus.
  DIABETES OBES METAB 2018 Oct 12. doi: 10.1111/dom.13555. (Epub ahead of print)
• Benesch C, Kuhlenkötter M, Heise T.
  Considering blood dilution improves the precision of continuous whole blood glucose measurements.
  J DIABETES SCI TECHNOL 2018 Sep 26. doi: 10.1177/1932296818803621. (Epub ahead of print)
• Schliess F, Heise T, Benesch C, Mianowska B, Stegbauer C, Broge B, Gillard P, Binkley G, Crone V, Carlier S, Delval C, Petkov A, Beck JP, Lodwig V, Gurdala M, Szecsenyi J, Rosenmöller M, Cypryk K, Mathieu C, Renard E, Heinemann L.
  Artificial pancreas systems for people with type 2 diabetes: Conception and design of the European CLOSE project.
  J Diabetes Sci Technol 2018 Sep 21. doi: 10.1177/1932296818803588. (Epub ahead of print)
• DeVries JH, Desouza C, Bellary S, Unger J, Hansen OKH, Zacho J, Woo V.
  Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
  DIABETES OBES METAB 20: 2426-2434, 2018. 
• Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L.
  MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
  Lancet 2018 Jun 30; 391: 2607-2618. 
• Heise T, Heckermann S, DeVries JH.
  Variability of insulin degludec and glargine U300: A matter of methodology or just marketing?
  DIABETES OBES METAB 2018 May 17. doi: 10.1111/dom.13365. (Epub ahead of print)
• Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T.
  Ultra-rapid BioChaperone Lispro improves post-prandial blood glucose excursions versus insulin lispro in a 14-day crossover treatment study in patients with type 1 diabetes.
  DIABETES OBES METAB 20: 2627-2632, 2018
• Forst T, Alghdban MK, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L.
  Sequential treatment escalation with dapagliflozin and saxagliptin improves beta cell function in type 2 diabetic patients on previous metformin treatment: An exploratory mechanistic study.
  HORM METAB RES 2018 May 4. doi: 10.1055/a-0591-9442. (Epub ahead of print)
• Moser O, Eckstein ML, McCarthy O, Deere R, Bain SC, Haahr HL, Zijlstra E, Heise T, Bracken RM.
  Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes.
  PLOS ONE 2018 Apr 2. doi: 10.1371/journal.pone.0194750. eCollection 2018.
• Olafsdottir AF, Polonsky W, Bolinder J, Hirsch IB, Dahlqvist S, Wedel H, Nyström T, Wijkman M, Schwarcz E, Hellman J, Heise T, Lind M.
  A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3).
  DIABETES TECHNOL THER 20: 274-284, 2018
• Zijlstra E.
  Analysis of "laboratory and benchtop performance of a mealtime insulin delivery system".
  J DIABETES SCI TECHNOL 2018 Apr 1. doi: 10.1177/1932296818767940. (Epub ahead of print)
• Ruan Y, Bally L, Thabit H, Leelarathna L, Hartnell S, Tauschmann M, Wilinska ME, Evans ML, Kojzar H, Dellweg S, Benesch C, Arnolds S, Pieber TR, Hovorka R.
  Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes.
  DIABETES OBES METAB 2018 Mar 25. doi: 10.1111/dom.13304. (Epub ahead of print)
• Stinkens R, van der Kolk BW, Jordan J, Jax T, Engeli S, Heise T, Jocken JW, May M, Schindler C, Havekes B, Schaper N, Albrecht D, Kaiser S, Hartmann N, Letzkus M, Langenickel TH, Goossens GH, Blaak EE.
  The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.
  SCI REP 2018 Mar 2; 8 (1): 3933.doi.10.1038/s41598-018-22194-z
• Zijlstra E, Coester HV, Heise T, Plum-Mörschel L, Rasmussen O, Rikte T, Pedersen LK, Qvist M, Sparre T.
  Injecting without pressing a button: An explanatory study of a shield-triggered injection mechanism.
  DIABETES OBES METAB 2017 Dec 27. doi: 10.1111/dom.13203. (Epub ahead of print)
• Hövelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, Moller DV, Heise T.
  Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog.
  DIABETES CARE 2017 Dec 22. doi: 10.2337/dc17-1402. (Epub ahead of print)
• Engeli S, Stinkens R, Heise T, May M, Goossens GH, Blaak EE, Havekes B, Jax T, Albrecht D, Pal P, Tegtbur U, Haufe S, Langenickel TH, Jordan J.
  Effect of sacubitril/valsartan on exercise-induced lipid metabolism in patients with obesity and hypertension.
  HYPERTENSION 71: 70-77, 2018
• Moser O, Eckstein ML, McCarthy O, Deere R, Bain SC, Haahr HL, Zijlstra E, Bracken RM.
  Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetes.
  DIABETOLOGY & METABOLIC SYNDROME 2017, 9:93. DOI: 10.1186/s13098-017-0294-1
• Zijlstra E, Jahnke J, Fischer A, Kapitza C, Forst T.
  Impact of injection speed, volume, and site on pain sensation.
  J DIABETES SCI TECHNOL 2017 Oct 1. doi: 10.1177/1932296817735121. (Epub ahead of print)
• Barnard KD, Kropff J, Choudhary P, Neupane S, Bain SC, Kapitza C, Forst T, Link M, Mdingi C, DeVries JH.
  Acceptability of implantable continuous glucose monitoring sensor.
  J DIABETES SCI TECHNOL 2017 Oct 1. doi: 10.1177/1932296817735125. (Epub ahead of print)
• Heise T, Kaplan K, Haahr HL.
  Day-to-day and within-day variability in glucose-lowering effect between insulin degludec and insulin glargine (100 U/mL and 300 U/mL): A comparison across studies.
  J DIABETES SCI TECHNOL 2017 Sep 1. doi: 10.1177/1932296817731422. (Epub ahead of print)
• Zijlstra E, Demissie M, Graungaard T, Heise T, Nosek L, Bode B.
  Investigation of pump compatibility of fast-acting insulin aspart in subjects with type 1 diabetes.
  J DIABETES SCI TECHNOL 2018; 12: 145-151
• Harris C, Forst T, Heise T, Plum-Mörschel L, Watkins E, Zhang Q, Fan L, Garhyan P, Porksen N.
  Hypoglycemia risk related to double dose is markedly reduced with basal insulin peglispro versus insulin glargine in patients with type 2 diabetes mellitus in a randomized trial: IMAGINE 8.
  DIABETES TECHNOL THER 19: 463-470, 2017
• Heise T, Biester T.
  Pharmakologische Eigenschaften des schneller wirksamen Insulins aspart (Faster-acting Insulin aspart). 
  Pharmacological properties of faster-acting insulin aspart (Faster-acting Insulin aspart).
  DIABETOLOGIE UND STOFFWECHSEL 2017 Aug 11. doi: // 10.1055/s-0043-116018. (Epub ahead of print) 
• Bally L, Thabit H, Ruan Y, Mader JK, Kojzar H, Dellweg S, Benesch C, Hartnell S, Leelarathna L, Wilinska ME, Evans ML, Arnolds S, Pieber TR, Hovorka R.
  Bolusing frequency and amount impacts glucose control during hybrid closed-loop.
  DIABET MED 2017 Jul 29. doi: 10.1111/dme.13436. (Epub ahead of print)
• Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC.
  The effect of empagliflozin on muscle sympathetic nerve activity in patients with type 2 diabetes mellitus.
  J AM SOC HYPERTENS 2017 Jul 21. doi: 10.1016/jash.2017.07.005. (Epub ahead of print)
• Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C.
  Introduction of similar insulins in Europe.
  DIABET MED 2017 Jun 13. doi: 10.1111/dme.13400. (Epub ahead of print)
• Heise T, Hövelmann U, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H.
  Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions: response to the commentary by Nuggehally R. Srinivas.
  CLIN DRUG INVEST 2017 Jun 8. doi: 10.1007/s40261-017-0539-7. (Epub ahead of print)
• Goldman J, Kapitza C, Pettus J, Heise T.
  Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
  CURR MED RES OPIN 2017 May 24: 1-26. doi: 10.1080/03007995.1335192. (Epub ahead od print) 
• Kenny HC, Rudwill F, Breen L, Salanova M, Blottner D, Heise T, Heer M, Blanc S, O'Gorman DJ.
  Bed rest and resistive vibration exercise unveil novel links between skeletal muscle mitochondrial function and insulin resistance.
  DIABETOLOGIA 2017 May 12. doi: 10.1007/s00125-017-4298-z. (Epub ahead of print)
• Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A.
  Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
  DIABETOLOGIA 60 (8): 1390-1399, 2017
• Emami A, Wilinska ME, Thabit H, Leelarathna L, Dellweg S, Benesch C, Mader JK, Holzer M, Kojzar H, Pieber TR, Arnolds S, Evans ML, Hovorka R.
  Behavioral patterns and associations with glucose control during 12-week randomized free-living clinical trial of day and night hybrid closed-loop insulin delivery in adults with type 1 diabetes.
  DIABETES TECHNOL THER 2017 May 2. doi: 10.1089/dia.2016.0307. (Epub ahead of print)
• Meier JJ, Schenker N, Kahle M, Schliess F, Kapitza C, Menge BA.
  Impact of insulin glargine and lixisenatide on beta cell function in patients with type 2 diabetes mellitus: a randomized open-label study.
  DIABETES OBES METAB 19: 1625-1629, 2017
• Barnard KD, Wysocki T, Ully V, Mader JK, Pieber TR, Thabit H, Tauschmann M, Leelarathna L, Hartnell S, Acerini CL, Wilinska ME, Dellweg S, Benesch C, Arnolds S, Holzer M, Kojzar H, Campbell F, Yong J, Picchierri J, Hindmarsh P, Heinemann L, Evans ML, Hovorka R.
  Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: A psychosocial substudy.
  J DIABETES SCI TECHNOL 2017 Apr 1. doi: 10.1177/1932296817702656. (Epub ahead of print)
• Wysham C, Bonadonna RC, Aroda VR, Puig-Domingo M, Kapitza C, Stager W, Yu C, Niemoeller E, Souhami E, Bergenstal RM, LixiLan-L trial investigators.
  Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
  DIABETES OBES METAB 2017 Apr 6. doi: 10.1111/dom. 12961. (Epub ahead of print) 
• Ruan Y, Thabit H, Leelarathna L, Hartnell S, Wilinska ME, Tauschmann M, Dellweg S, Benesch C, Mader JK, Holzer M, Kojzar H, Evans ML, Pieber TR, Arnolds S, Hovorka R on behalf of AP@home consortium.
  Faster insulin action is associated with improved outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes.
  DIABETES OBES METAB 2017. doi: 10.1111/dom.12956 (Epub ahead of print)
• Jax T, Stirban A, Terjung A, Esmaeli H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.
  A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
  CARDIOVASC DIABETOL 2017 JAN 21; 16: 13
• Heise T, Norskov M, Nosek L, Kaplan K, Famulla S, Haahr HL.
  Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes.
  DIABETES OBES METAB 2017 Mar 14. doi: 10.1111/dom.12938 (Epub ahead of print)
• Heise T, Pieber TR, Danne T, Erichsen L, Haahr H.
  A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes.
  CLIN PHARMACOKINET 2017 Feb 15. doi: 10.1007/s40262-017-0514-8. (Epub ahead of print)
• Hövelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KM, Haahr H.
  Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions.
  CLIN DRUG INVESTIG 37: 503-509, 2017  
• Forst T, Plum-Mörschel L, Weber MM.
  Cardiovascular aspects of diabetes treatment: Finally a reason for cardiologists to be pleased.
  INTERNIST (Berl.) 2017 Jan 24. doi: 10.1007/s00108-017-0189-0. (Epub ahead of print). (German)
• Riddell MC, Gallen IW, Smart CE, Taplin CE, Adolfsson P, Lumb AN, Kowalski A, Rabasa-Lhoret R, McCrimmon RJ, Hume C, Annan F, Fournier PA, Graham C, Bode B, Galassetti P, Jones TW, Millan IS, Heise T, Peters AL, Petz A, Laffel LM.
  Exercise management in type 1 diabetes: a consensus statement.
  LANCET DIABETES ENDOCRINOL 2017 Jan 23. doi: 10.1016/S2213-8587(17)30014-1. (Epub ahead of print)
• Kuhlenkötter M, Heise T, Benesch C.
  Improved algorithm for automated glucose clamps.
  DIABETES TECHNOL THER 19: 124-130, 2017 
• Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, Schwarz E, Olafsdottir AF, Frid A, Wedel H, Ahlen E, Nyström T, Hellman J.
  Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial.
  JAMA 317: 379-387, 2017
• Forst T, Falk A, Andersen G, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L.
  Effects on alpha- and beta-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
  DIABETES OBES METAB 19: 489-495, 2017
• Reed TL, Drozda JP Jr, Baskin KM, Tcheng J, Conway K, Wilson N, Marinac-Dabic D, Heise T, Krucoff MW.
  Advancing medical device innovation through collaboration and coordination of structured data capture pilots: Report from the Medical Device Epidemiology Network (MDEpiNet) specific, measurable, achievable, results-oriented, time bound (SMART) think tank.
  HEALTHc (Amst). 2016 Dec 6. doi: 10.1016/j.hjdsi.2016.10.004. (Epub ahead of print)
• Kapitza C., Nowotny I., Lehmann A., Bergmann K., Rotthaeuser B., Nosek L., Becker R..
  Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog® in subjects with type 1 diabetes.
  DIABETES OBES METAB 19: 622-627, 2017
• Forst T, Zijlstra E. 
  Glukoseselbstmessung - technische Möglichkeiten und Limitationen.
  Diabetologie 11: 51-50, 2016
• de la Pena A, Loghin C, Cui X, Zhang X, Kapitza C, Kelly RP.
  Once weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
  DIABETES OBES METAB 19: 517-523, 2017
• Porksen N, Linnebjerg H, Garhyan P, Lam ECQ, Knadler MP, Jacober SJ, Hoevelmann U, Plum-Moerschel L, Watkins E, Gastaldelli A, Heise T.
  Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
  DIABETES OBES METAB 19: 482-488, 2017
• Heise T, Stender-Petersen K, Hövelmann U, Jacobsen JB, Nosek L, Zijlstra E, Haahr H.
  Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus.
  CLIN PHARMACOKINET 2016 Nov 22. doi: 10.1007/s40262-016-0473-5. (Epub ahead of print)
• Heise T, Hövelmann U, Zijlstra E, Stender-Petersen K, Jacobsen JB, Haahr H.
  A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus.
  DRUGS AGING 34 (1): 29-38, 2017
• Kropff J, Choudhary P, Neupane S, Barnard K, Bain SC, Kapitza C, Forst T, Link M, Dehennis A, DeVries JH.
  Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE Study: A 180-day, prospective, multicenter, pivotal trial.
  DIABETES CARE 2016 Nov 4. doi: 10.2337/dc16-1525. (Epub ahead of print)
• Heise T, Zijlstra E, Nosek L, Rikte T, Haahr H.
  Pharmacological properties of faster-acting insulin aspart versus insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomised, double-blind, crossover trial.
  DIABETES OBES METAB 19: 208-215, 2017
• Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC.
  Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes.
  CLIN THER 38: 2265-2275, 2016
• Haahr H, Fita EG, Heise T.
  A review of insulin degludec/insulin aspart: Pharmacokinetic and pharmacodynamic properties and their implications in clinical use.
  CLIN PHARMACOKINET 2016 Oct 1. doi: 10.1007/s40262-016-0455-7. (Epub ahead of print) 
• Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC.
  Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus.
  CLIN THER 38: 2248-2264, 2016
• Siegmund T, Pfohl M, Forst T, Pscherer S, Bramlage P, Foersch J, Borck A, Seufert J.
  Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.
  DIABETES METAB SYNDR 2016 Aug 24. doi: 10.1016/j.dsx.2016.08.006. (Epub ahead of print) 
• Jordan J, Stinkens R, Jax T, Engeli S, Blaak EE, May M, Havekes B, Schindler C, Albrecht D, Pal P, Heise T, Goossens GH, Langenickel TH.
  Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension.
  CLIN PHARMACOL THER 2016 Aug 20. doi: 10.1002/cpt.455.(Epub ahead of print)
• Zijlstra E, Heinemann L, Fischer A, Kapitza C.
  A comprehensive performance evaluation of five blood glucose systems in the hypo-, eu-, and hyperglycemic range.
  J DIABETES SCI TECHNOL 10: 1316-1323, 2016.
• Heise T, Mathieu C.
  Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.
  DIABETES OBES METAB 2016 Sep 4. doi: 10.1111/dom.12782. (Epub ahead of print)
• Linnebjerg H, Lam EC, Zhang X, Seger ME, Coutant D, Chua L, Kapitza C, Heise T.
  Duration of action of two insulin glargine products, LY2963016 insulin glargine and lantus insulin glargine, in subjects with type 1 diabetes mellitus.
  DIABETES OBES METAB 2016 Aug 3. doi: 10.1111/dom.12759. (Epub ahead of print)
• Famulla S, Hövelmann U, Fischer A, Coester HV, Hermanski L, Kaltheuner M, Kaltheuner L, Heinemann L, Heise T, Hirsch L.
  Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action, and impaired postprandial glucose control.
  DIABETES CARE 39: 1486-1492, 2016
• Heise T, Zijlstra E, Nosek L, Heckermann S, Plum-Mörschel L, Forst T.
  The euglycaemic glucose clamp: What it can and cannot do - and how to do it.
  DIABETES OBES METAB 18: 972-982, 2016
• Leelarathna L, Thabit H, Hartnell S, Wilinska ME, Dellweg S, Benesch C, Mader JK, Holzer M, Kojzar H, Evans ML,
  Arnolds S, Pieber TR, Hovorka R, on behalf of the AP@home Consortium.
  Rapid benefits of structured optimization and sensor-augmented insulin pump therapy in adults with type 1 diabetes.
  J DIABETES SCI TECHNOL 11: 180-181, 2017
• Forst TA, Plum-Mörschel L, Heise T.
  Pharmacological intervention in type 2 diabetes mellitus - A pathophysiologically reasoned approach?
  CURR DIABETES REV 2016 Jun 13. (Epub ahead of print)
• Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, Pehrsson NG, Moström P.
  Design and methods of a randomized trial of continuous glucose monitoring in persons with type 1 diabetes with impaired glycemic control treated with multiple daily insulin injections (GOLD Study).
  J DIABETES SCI TECHNOL 2016 Apr 13. pii: 1932296816642578. (Epub ahead of print)
• Ruan Y, Thabit H, Leelarathna L, Hartnell S, Wilinska ME, Dellweg S, Benesch C, Mader JK, Holzer M, Kojzar H, Evans ML, Pieber TR, Arnolds S, Hovorka R, on behalf of the AP@home Consortium.
  Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes.
  DIABETES CARE 39: 830-832, 2016
• Muscelli E, Astiarraga B, Barsotti E, Mari A, Schliess F, Nosek L, Heise T, Broedl UC, Woerle HJ, Ferrannini E.
  Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
  DIABETOLOGIA 59:700-708, 2016
• Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Pieber TR, Muscelli E.
  Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients.
  DIABETES 2016 Feb 9. pii:db151356 (Epub ahead of print)
• Freude S, Heise T, Wörle H-J, Jungnik A, Rauch T, Hamilton B, Schölch C, Huang F, Gräfe-Mody U.
  Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11beta-HSD1 inhibitor in humans: Liver and adipose tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks.
  DIABETES OBES METAB 18: 483-490, 2016 
• Forst T. Kapitza C (eds.)
  Clinical advances in diabetes mellitus.
  FUTURE SCIENCE LTD, London, 2015
• Heinemann L, Zijlstra E, Pleus S, Freckmann G.
  Performance of blood glucose meters in the hypoglycemic range: current evaluations indicate that this is not sufficient from a clinical point of view.
  DIABETES CARE 38: e139-e140, 2015
• Stirban A, Tschöpe D.
  Vascular effects of dietary advanced glycation end products.
  INT J ENDOCRINOL 2015. doi: 10.1155/2015/836498
• Heer M, Egert S.
  Nutrients other than carbohydrates: their effects on glucose homeostasis in humans.
  DIABETES MEATB RES REV 31: 14-35, 2015
• Forst T, Koch C, Dworak M.
  Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study.
  CURR MED RES OPIN 31: 1079-1084, 2015
• Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S.
  Effect of canagliflozin on liver function tests in patients with type 2 diabetes.
  DIABETES METAB 42: 25-32, 2016
• Forst T, Michelson G, Diessel S, Jahnke J, Kapitza C.
  Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients.
  J HYPERTENS 34: 345-350, 2016
• Heise T. Bain SC, Bracken RM, Zijlstra E, Nosek L, Stender-Petersen K, Rabol R, Rowe E, Haahr HL.
  Similar risk of exercise-related hypoglycaemia for insulin degludec compared with insulin glargine in patients with type 1 diabetes: a randomised cross-over trial. 
  DIABETES OBES METAB 18: 196-199, 2016  
• Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, Acerini CL, Dellweg S, Benesch C, Heinemann L, Mader JK, Holzer M, Kojzar H, Exall J, Yong J, Pichierri J, Barnard KD, Kollman C, Cheng P, Hindmarsh PC, Campbell FM, Arnolds S, Pieber TR, Evans ML, Dunger DB, Hovorka R; APCam Consortium and AP@home Consortium.
  Home use of an artificial beta cell in type 1 diabetes
  N ENGL J MED 2015 Sep 17. doi: 10.1056/NEJMoa1509351. (Epub ahead of print)
• Marquard J, Stirban A, Schliess F, Sievers F, Welters A, Otter S, Fischer A, Wnendt S, Meissner T, Heise T, Lammert E.
  Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: A randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.
  DIABETES OBES METAB 2015 Sep 12. doi: 10.1111/dom.12576. (Epub ahead of print)
• Blauw H, Wendl I, DeVries JH, Heise T, Jax T.
  Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels.
  DIABETES OBES METAB 2015 Sep 7. doi: 10.1111/dom.12571. (Epub ahead of print)
• Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, Woerle HJ, Broedl UC, Kaspers S.
  Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
  DIABETES OBES METAB 2015. doi: 10.1111/dom.12494
• Heise T, Hövelmann U, Nosek L, Hermanski L, Bottcher SG, Haahr H.
  Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
  EXPERT OPIN DRUG METAB TOXICOL 11: 1193-1201, 2015.
• Rini CJ, McVey E, Sutter D, Keith S, Kurth HJ, Nosek L, Kapitza C, Rebrin K, Hirsch L, Pettis RJ.
  Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear.
  DRUG DELIV TRANSL RES 5: 332-345, 2015
• Thabit H, Leelarathna L, Wilinska ME, Elleri D, Allen JM, Lubina-Solomon A, Walkinshaw E, Stadler M, Choudhary P, Mader JK, Dellweg S, Benesch C, Pieber TR, Arnolds S, Heller SR, Amiel SA, Dunger D, Evans ML, Hovorka R.
  Accuracy of continuous glucose monitoring during three closed-loop home studies under free-living conditions.
  DIABETES TECHNOL THER 17: 801-807, 2015
• Benesch C, Heise T, Klein O, Heinemann L, Arnolds S.
  How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated clamp device.
  J DIABETES SCI TECHNOL 9: 792-800, 2015.
• Heise T, Hövelmann U, Brondsted L, Adrian CL, Nosek L, Haahr H.
  Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
  DIABETES OBES METAB 17: 682-688, 2015.
• Meier JJ, Rosenstock J, Hincelin-Mery A, Roy-Duval C, Delfolie A, Coester HV, Menge BA, Forst T, Kapitza C.
  Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial.
  DIABETES CARE 38: 1263-1273, 2015.
• Heise T, Nosek L, Klein O, Coester H, Svendsen AL, Haahr H.
  Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
  DIABETES OBES METAB 17: 659-664, 2015.
• Arnolds S, Heckermann S, Heise T, Sawicki PT.
  Spectrum of diabetes research does not reflect patients`scientific preferences: A longitudinal evaluation of diabetes research areas 2010-2013 vs. a cross-sectional survey in patients with diabetes.
  EXP CLIN ENDOCRINOL DIABETES 123: 299-302, 2015.
• Kapitza C, Bode B, Ingwersen SH, Jacobsen LV, Poulsen P.
  Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy.
  J CLIN PHARMACOL 2015 May 21. doi: 10.1002/jcph.549. (Epub ahead of print)
• Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A.
  Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
  J CLIN PHARMACOL 55: 497-504, 2015.
• Boronikolos GC, Menge BA, Schenker N, Breuer TG, Otte JM, Heckermann S, Schliess F, Meier JJ.
  Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance.
  DIABETOLOGIA 58: 1175-1182, 2015
• Marquard J, Otter S, Welters A, Stirban A, Fischer A, Eglinger J, Herebian D, Kletke O, Klemen MS, Stožer A, Wnendt S, Piemonti L, Köhler M, Ferrer J, Thorens B, Schliess F, Rupnik MS, Heise T, Berggren PO, Klöcker N,Meissner T, Mayatepek E, Eberhard D, Kragl M, Lammert E.
  Characterization of pancreatic NMDA receptors as possible drug targets for diabetestreatment.
  Nat Med. 21: 363-72, 2015. 
• Heise T, Mattheus M, Woerle HJ, Broedl UC, Macha S.
  Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
  CLIN THER 37: 793-803, 2015.
• Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, Segel S, Kapur R, Haahr H, Hompesch M
  Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action.
  J DIABETES 2015 Jan 12. doi: 10.1111/1753-0407.12266. (Epub ahead of print)
• Shiramoto M, Eto T, Irie S, Fukuzaki A, Teichert L, Tillner J, Takahashi Y, Koyama M, Dahmen R, Heise T, Becker RH.
  Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
  DIABETES OBES METAB 17: 254-260, 2015.
• Arnolds S, Sawicki PT.
  Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.
  DIABETS CARE 2015 Feb; 38(2):e25. doi: 10.2337/dc14-2418.
• Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T.
  New insulin glargine 300 units/ml provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units/ml.
  DIABETES CARE 38: 637-643, 2015. 
• Marquard J, Otter S, Welters A, Stirban A, Fischer A, Eglinger J, Herebian D, Kletke O, Klemen MS, Stožer A, Wnendt S, Piemonti L, Köhler M, Ferrer J, Thorens B, Schliess F, Rupnik MS, Heise T, Berggren PO, Klöcker N,Meissner T, Mayatepek E, Eberhard D, Kragl M, Lammert E.
  Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment.
  Nat Med. 2015 Apr;21(4):363-72. doi: 10.1038/nm.3822. Epub 2015 Mar 16.
• Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, Segel S, Kapur R, Haahr H, Hompesch M.
  Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action.
  J DIABETES 2015 Jan 12. doi: 10.1111/1753-0407.12266. (Epub ahead of print)
• Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A.
  Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
  J CLIN PHARMACOL 2014 Dec 5. doi: 10.1002/jcph.443. (Epub ahead of print)
• Becker RH, Nowotny I, Teichert L, Bergmann K, Kapitza C.
  Low within- and between-day variability in exposure to new insulin glargine 300 U.mL-1.
  DIABETES OBES METAB 17: 261-267, 2015
• Shiramoto M, Eto T, Irie S, Fukuzaki A, Teichert L, Tillner J, Takahashi Y, Koyama M, Dahmen R, Heise T, Becker R.
  Single-dose new insulin glargine 300 U.mL-1 provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
  DIABETES OBES METAB 2014 Nov 26. doi: 10.1111/dom.12415. (Epub ahead of print)
• Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, Rothenberg P, Plum-Mörschel L.
  Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
  DIABETES OBES METAB 17: 188-197, 2015
• Becker RH, Stechl J, Msihid J, Kapitza C.
  Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes - a study in both people with type 2 diabetes and healthy subjects.
  DIABETES OBES METAB 16: 793-800, 2014
• Leelarathna L, Dellweg S, Mader JK, Allen JM, Benesch C, Doll W, Ellmerer M, Hartnell S, Heinemann L, Kojzar H, Michalewski L, Nodale M, Thabit H, Wilinska ME, Pieber TR, Arnolds S, Evans ML, Hovorka R, on behalf of the AP@home Consortium.
  Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study.
  DIABETES CARE 37: 1931-1937, 2014
• Heise T, Morrow L, Hompesch M, Häring HU, Kapitza C, Abt M, Ramsauer M, Magnone MC, Fuerst-Recktenwald S.
  Safety, efficacy and weight effect of two 11beta-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.
  DIABETES OBES METAB 16: 1070-1077, 2014
• Heise T, Larbig M, Patel S, Seck T, Hehnke U, Woerle HJ, Dugi K.
  The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of beta-cell function in type 2 diabetes.
  DIABETES OBES METAB 16: 1036-1039, 2014
• Dungan KM, Povedano ST, Forst T, Gonzales JG, Atisso C, Sealls W, Fahrbach JL.
  Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
  Lancet 384: 1349-1357, 2014
• Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H.
  Distinct prandial and basal glucose-lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus.
  DIABETES THER 5 (1): 255-265, 2014
• Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Mörschel L.
  Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus.
  DIABETES OBES METAB 2014, Jun 17. doi:10.1111/dom.12322 (Epub ahead of print)
• Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ.
  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
  J CLIN INVEST 124: 499-508, 2014
• Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P.
  Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
  DIABETES OBES METAB 2014 Feb 15. doi: 10.1111/dom.12273. [Epub ahead of print]
• Forst T, Anastassiadis E, Diessel S, Löffler A, Pfützner A.
  Effect of linagliptin compared to glimepiride on postprandial glucose metabolism, islet cell function, and vascular function parameters in patients with type 2 diabetes mellitus on ongoing metformin treatment.
  DIABETES METAB RES REV 2014 Jan 23. doi: 10.1002/dmrr.2525. [Epub ahead of print]
• Forst T, Weber MM, Mitry M, Müller L, Forst S, Tanis M, Pfützner A, Michelson G.
  Retinal microcirculation in type I diabetic patients with and without peripheral sensory neuropathy.
  J DIABETES SCI TECHNOL 8: 356-361, 2014
• Arnolds S, Heise T, Flacke F, Sieber J.
  Common standards of basal insulin titration in T2DM.
  J DIABETES SCI TECHNOL 7: 771-788, 2013
• Flint A, Kapitza C, Zdravkovic M.
  The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
  DIABETES OBES METAB 15: 958-962, 2013
• Frier BM, Russell-Jones D, Heise T.
  A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
  DIABETES OBES METAB 15: 978-986, 2013
• Greiner H, Schaller-Ammann R, Huber A, O’Connell M, Krejci J, Porro G, Korsatko S, Gurban J, Deller S, Brunner M, Berghofer A, Priedl J, Zijlstra E, Heise T, Pieber TR, Schaupp L.
  Continuous blood glucose monitoring (Cgm) system based on intravenous microdialysis and glucose sensing.
  BIOMED TECH (Berl). 2013 Sep 7.doi:pii: /j/bmte.2013.58.issue-s1-l/bmt-2013-4224/bmt-2013-4224.xml. doi: 10.1515/bmt-2013-4224. [Epub ahead of print]
• Heise T, Meneghini LF.
  Insulin stacking vs. therapeutic accumulation: understanding the differences.
  ENDOCR PRACT 20: 75-83, 2014
• Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ.
  Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
  DIABETES OBES METAB 15: 613-621, 2013
• Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S, Woerle HJ, Dugi K.
  Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.
  DIABETES THER 4: 331-345, 2013
• Kapitza C, Forst T, Coester H-V, Poitiers F, Ruus P, Hincelin-Mery A.
  Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
  DIABETES OBES METAB 15: 642-649, 2013
• Kolb H, Lückemeyer K, Heise T, Herder C, Schloot NC, Koenig W, Heinemann L, Martin S; DIATOR Study Group.
  The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial).
  PLOS ONE. 2013 Aug 26; 8(8):e72440. doi: 10.1371/journal.pone.0072440.
• Liebl A, Davidson J, Mersebach H, Dykiel P, Tack CJ, Heise T.
  A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.
  J DIABETES SCI TECHNOL 7: 1328-1336, 2013
• Luijf YM, Arnolds S, Avogaro A, Benesch C, Bruttomesso D, Farret A, Heinemann L, Place J, Renard E, Scotton R, DeVries JH, on behalf of the AP@home consortium.
  Patch pump versus conventional pump: Postprandial glycemic excursions and the influence of wear time.
  DIABETES TECHNOL THER 15: 575-579, 2013
• Luijf YM, Mader JK, Doll W, Pieber T, Farret A, Place J, Renard E, Bruttomesso D, Filippi A, Avogaro A, Arnolds S, Benesch C, Heinemann L, DeVries JH, on behalf of the AP@home consortium.
  Accuracy and reliability of continuous glucose monitoring systems: a head-to-head comparison.
  DIABETES TECHNOL THER 15: 722-727, 2013
• Luijf YM, DeVries JH, Zwinderman K, Leerathna L, Nodale M, Caldwell K, Kumareswaran K, Elleri D, Allen JM, Wilinska ME, Evans ML, Hovorka R, Doll W, Ellmerer M, Mader JK, Renard E, Place J, Farret A, Cobelli C, Del Favero S, Dalla Man C, Avogaro A, Bruttomesso D, Filippi A, Scotton R, Magni L, Lanzola G, Di Palma F, Toffanin C, Arnolds S, Benesch C, Heinemann L, on behalf of the AP@home consortium.
  Day and night closed-loop control in adults with type 1 diabetes mellitus.
  DIABETES CARE 36: 3882-3887, 2013
• Meier JJ, Pennartz C, Schenker N, Menge BA, Schmidt WE, Heise T, Kapitza C, Veldhuis JD.
  Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy.
  DIABETES OBES METAB 15:258-263, 2013
• Nosek L, Roggen K, Heinemann L, Gottschalk C, Kaiser M, Arnolds S, Heise T.
  Insulin aspart has a shorter duration of action than human insulin over a wide dose-range.
  DIABETES OBES METAB 15: 77-83, 2013
• Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P.
  Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
  J CLIN ENDOCRINOL METAB 98: E867-871, 2013
• Sinha VP, Howey DC, Choi SL, Mace KF, Heise T.
  Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
  DIABETES OBES METAB 16: 344-350, 2014
• Stirban A, Kotsi P, Franke K, Strijowski U, Cai W, Götting C, Tschoepe D.
  Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins.
  DIABETES CARE 36: 1278-1282, 2013
• Stirban A, Pop A, Tschoepe D.
  A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in type 2 diabetes.
  DIABET MED 30: 1204-1208, 2013
• Varkonyi T, Putz Z, Keresztes K, Martos T, Lengyel C, Stirban A, Jermendy G, Krempler P.
  Current options and perspectives in the treatment of diabetic neuropathy.
  CURR PHARM DES 19: 4981-5007, 2013
• Vora J, Heise T.
  Variability of glucose-lowering effect as limiting factor in optimizing basal insulin therapy: a review.
  DIABETES OBES METAB 15: 701-712, 2013
• Vora J, Heise T.
  Variability of glucose-lowering effect as a limiting factor in optimising basal insulin therapy. A review.
  DIABETES OBES METAB. Accepted manuscript online: 1 MAR 2013 06:08PM EST | DOI: 10.1111/dom.12087
• Heise T, Seewald-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Wörle HJ.
  Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 week´s treatment with empagliflozin once daily in patients with type 2 diabetes.
  DIABETES OBES METAB. 2013 Jan 28. doi: 10.1111/dom.12073.[Epub ahead of print]
• Arnolds S, Heckermann S, Koch C, Heissmann N, Sawicki PT.
  How do patients' Exp Clin Endocrinol Diabetespreferences compare to the present spectrum of diabetes research?EXP CLIN ENDOCRINOL DIABETES 121(1): 60-63, 2013
• Zijlstra E, Heise T, Nosek L, Heinemann L, Heckermann S.
  Continuous glucose monitoring: quality of hypoglycaemia detection.
  DIABETES OBES METAB 15(2):130-135, 2013
• Barkai L, Gurieva I, Stirban A, Tesfaye S, Czupryniak L, Mankovsky BN, Spallone V, Veresiu IA, Schnell O, Kempler P.
  Microvascular complications in children and adolescents with type 1 diabetes.
  DIABETES, STOFFWECHSEL UND HERZ 21: 309-315, 2012
• Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, HeiseT, Becker RH
  Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.
  DIABETES CARE 35(12): 2626 – 2630, 2012
• Buehlmeier J, Frings-Meuthen P, Remer T, Maser-Gluth C, Stehle P, Biolo G, Heer M.
  Alkaline salts to counteract bone resorption and protein wasting induced by high salt intake: Results of a randomized controlled trial.
  J CLIN ENDOCRINOL METAB. 97(12): 4789-4797, 2012
• Caduff A, Heinemann L, Talary MS, Di Benedetto G, Lutz HU, Theander S.
  A 4-h hyperglycaemic excursion induces rapid and slow changes in major electrolytes in blood in healthy human subjects.
  ACTA DIABETOLOGIA 49(5):333-339, 2012
• Facchinetti A, Sparacino G, Guerra S, Luijf M, De Vries JH, Mader JK, Ellmerer M, Benesch C, Heinemann L, Bruttomesso D, Avogaro A, Cobelli C.
  Real-time improvement of continuous glucose-monitoring accuracy: the smart sensor concept.
  DIABETES CARE PMID: 23172973 (Epub ahead of print), 2012
• Heise T; Merker L, Matthaei S.
  Insulin degludec: Ein neues, ultra-langwirksames Basalinsulin.
  DIABETES, STOFFWECHSEL UND HERZ 21: 231-238, 2012
• Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H.
  Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
  DIABETES OBES METAB. 14(10): 944-950, 2012
• Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H.
  Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
  DIABETES OBES METAB 14(9): 859-864, 2012
• Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.
  Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
  DIABETES RES CLIN PRACT. 97(2): 258-266, 2012
• Luijf YM, Avogaro A, Benesch C, Bruttomesso D, Cobelli C, Ellmerer M, Heinemann L, Mader JK, De Vries JH.
  Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research center.
  J DIABETES SCI TECHNOL. 6(5): 1103-1106, 2012
• McVey E, Hirsch L, Sutter DE, Kapitza C, Dellweg S, Clair J, Rebrin K, Judge K, Pettis RJ.
  Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
  J DIABETES SCI TECHNOL. 6(4):743-754, 2012
• Morgan JL, Zwart SR, Heer M, Ploutz-Snyder R, Ericson K, Smith SM.
  Bone metabolism and nutritional status during 30-day head-down tilt bed rest.
  J APPL PHYSIOL. 113(10):1519-1529, 2012
• Nosek L, Cardot JM, Owens DR, Ibarra P, Bagate K, Vergnault G, Kaiser K, Fischer A, Heise T.
  Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus.
  DIABETES OBES METAB. 14(12):1137-1144, 2012
• Plum L, Lin HV, Aizawa K, Liu Y, Wardlaw SL, Accili D.
  InsR/FoxO1 signaling curtails hypothalamic POMC neuron number.
  PLoS ONE 7: e31487, 2012
• Rauch T, Graefe-Mody U, Deacon CF, Ring A, Holst JJ, Woerle HJ, Dugi KA, Heise T.
  Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.
  DIABETES THER. 3(1):10.1007/s13300-012-0010-y [doi]
• Ren H, Orozco IJ, Su Y, Suyama S, Gutiérrez-Juárez R, Horvath TL, Wardlaw SL, Plum L, Arancio O, Accili D.
  FoxO1 target Gpr17 activates AgRP neurons to regulate food intake.
  CELL 149(6): 1341–1326, 2012
• Smith SM, Heer M, Wang Z, Huntoon CL, Zwart SR.
  Long-duration space flight and bed rest effects on testosterone and other steroids.
  JCEM 97(1):270-8, 2012
• Smith SM, Heer M, Shackelford L, Sibonga JD, Ploutz-Snyder L, Zwart SR.
  Benefits for bone from resistance exercise and nutrition in long-duration spaceflight: Evidence from biochemistry and densitometry.
  J BONE MINER RES. 27(9):1896-906, 2012
• Stirban A, Dellweg S.
  Neue Methoden zur Diagnose mikrovaskulärer Komplikationen.
  DIABETES CONGRESS REPORT 5: 22-25, 2012
• Stirban A, Nandrean S, Kirana S, Götting C, Veresiu IA, Tschoepe D.
  Benfotiamine counteracts smoking induced vascular dysfunction in healthy smokers.
  MED. doi:10.1155/2012/968761, 2012
• Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, Heise T, Heinemann L, Roden M, Schloot NC.
  Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).
  PLoS One 7(3):e33108, 2012
• Thomas A, Heinemann L.
  Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study.
  J DIABETES SCI TECHNOL. 6(3): 572-580, 2012
• Zwart SR, Gibson CR, Mader TH, Ericson K, Heer M, Smith SM.
  Vision changes after spaceflight are related are related to alterations in folate- and vitamin B-12 dependent one-carbon metabolism.
  J NUTR. 142(3): 427-31, 2012
• Heer M.
  An analysis of the effect of olibra: a 12-week randomized control trial and a review of earlier studies.
  J DIABETES SCI TECHNOL 6(3): 709-711, 2012
• Tigges C, Heer M.
  The second-meal effect: can meal-skipping and nutrient composition of a meal affect postprandial blood glucose levels from a subsequent meal?
  DIABET NUTRITJE RISK CARDIOMETABOLIC 3: 33-39, 2012
• Liebl A, Henrichs HR, Heinemann L, Freckmann G, Biermann E, Thomas A.
  Für die Arbeitsgruppe CGM der Arbeitsgemeinschaft Diabetologische Technologie der DDG (AGDT) Evidenz und Konsens für den klinischen Einsatz von CGM.
  DIABETES, STOFFWECHSEL UND HERZ 1: 32-47, 2012
• Stirban A, Nandrean S, MD, Kirana S, Christian Götting C, Andrei Veresiu IA, Tschoepe D.
  Benfotiamine counteracts smoking induced vascular dysfunction in healthy smokers.
  INT J VASC MED, Volume 2012, Article ID 968761, doi:10.1155/2012/968761
•